image
Ardelyx, Inc. ARDX
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 4.68
-5.3 %
$ 1.12 B
Market Cap
-26.82
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ARDX stock under the worst case scenario is HIDDEN Compared to the current market price of 4.68 USD, Ardelyx, Inc. is HIDDEN

ARDX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ARDX stock under the base case scenario is HIDDEN Compared to the current market price of 4.68 USD, Ardelyx, Inc. is HIDDEN

ARDX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ARDX stock under the best case scenario is HIDDEN Compared to the current market price of 4.68 USD, Ardelyx, Inc. is HIDDEN

ARDX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ARDX

image
1M -4%
6M -28.0%
1Y -86%
3Y 416%
5Y 169%
All
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
334 M REVENUE
168.06%
Growth Rates
1Year 168.06%
3Years 220.89%
5Years 129.14%
7Years 34.45%
10Years 26.57%
-28 M OPERATING INCOME
55.83%
Growth Rates
1Year 55.83%
3Years 43.42%
5Years 21.07%
7Years 11.38%
10Years -33.42%
-39.1 M NET INCOME
40.76%
Growth Rates
1Year 40.76%
3Years 37.22%
5Years 16.24%
7Years 6.86%
10Years -28.40%
-44.8 M OPERATING CASH FLOW
50.06%
Growth Rates
1Year 50.06%
3Years 33.53%
5Years 10.14%
7Years 5.21%
10Years -15.82%
-18.3 M INVESTING CASH FLOW
86.04%
Growth Rates
1Year 86.04%
3Years -10.78%
5Years -12.27%
7Years -3.60%
10Years -25.73%
107 M FINANCING CASH FLOW
-27.14%
Growth Rates
1Year -27.14%
3Years 8.70%
5Years -7.27%
7Years 105.66%
10Years 5.69%
116 M REVENUE
18.21%
Growth Rates
1Year 168.06%
3Years 220.89%
5Years 129.14%
7Years 34.45%
10Years 26.57%
8.12 M OPERATING INCOME
263.86%
Growth Rates
1Year 55.83%
3Years 43.42%
5Years 21.07%
7Years 11.38%
10Years -33.42%
4.64 M NET INCOME
674.17%
Growth Rates
1Year 40.76%
3Years 37.22%
5Years 16.24%
7Years 6.86%
10Years -28.40%
9.81 M OPERATING CASH FLOW
1858.08%
Growth Rates
1Year 50.06%
3Years 33.53%
5Years 10.14%
7Years 5.21%
10Years -15.82%
-41.6 M INVESTING CASH FLOW
-1777.87%
Growth Rates
1Year 86.04%
3Years -10.78%
5Years -12.27%
7Years -3.60%
10Years -25.73%
49.3 M FINANCING CASH FLOW
1728.44%
Growth Rates
1Year -27.14%
3Years 8.70%
5Years -7.27%
7Years 105.66%
10Years 5.69%
Balance Sheet Ardelyx, Inc.
image
Current Assets 356 M
Cash & Short-Term Investments 250 M
Receivables 57.7 M
Other Current Assets 48.6 M
Non-Current Assets 79.3 M
Long-Term Investments 0
PP&E 3.88 M
Other Non-Current Assets 75.4 M
57.39 %13.24 %11.16 %17.31 %Total Assets$435.8m
Current Liabilities 77.8 M
Accounts Payable 16 M
Short-Term Debt 1.56 M
Other Current Liabilities 60.3 M
Non-Current Liabilities 185 M
Long-Term Debt 152 M
Other Non-Current Liabilities 32.8 M
6.10 %22.96 %57.87 %12.48 %Total Liabilities$262.5m
EFFICIENCY
Earnings Waterfall Ardelyx, Inc.
image
Revenue 334 M
Cost Of Revenue 50.6 M
Gross Profit 283 M
Operating Expenses 311 M
Operating Income -28 M
Other Expenses 11.2 M
Net Income -39.1 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)334m(51m)283m(311m)(28m)(11m)(39m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.85% GROSS MARGIN
84.85%
Averages
1Year 84.85%
3Years 87.55%
5Years 90.17%
7Years 88.80%
10Years 89.28%
-8.38% OPERATING MARGIN
-8.38%
Averages
1Year -8.38%
3Years -60.49%
5Years -581.83%
7Years -1160.84%
10Years -887.31%
-11.73% NET MARGIN
-11.73%
Averages
1Year -11.73%
3Years -64.56%
5Years -601.17%
7Years -1186.52%
10Years -904.99%
-22.58% ROE
-22.58%
Averages
1Year -22.58%
3Years -43.51%
5Years -79.35%
7Years -75.21%
10Years -65.80%
-8.98% ROA
-8.98%
Averages
1Year -8.98%
3Years -22.18%
5Years -43.77%
7Years -43.60%
10Years -42.40%
-7.83% ROIC
-7.83%
Averages
1Year -7.83%
3Years -25.24%
5Years -48.60%
7Years -47.92%
10Years -46.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ardelyx, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -39.1 M
Depreciation & Amortization 2.06 M
Capital Expenditures -1.01 M
Stock-Based Compensation 37.4 M
Change in Working Capital -49.2 M
Others 27.4 M
Free Cash Flow -45.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ardelyx, Inc.
image
Wall Street analysts predict an average 1-year price target for ARDX of $11.6 , with forecasts ranging from a low of $8 to a high of $15 .
ARDX Lowest Price Target Wall Street Target
8 USD 70.94%
ARDX Average Price Target Wall Street Target
11.6 USD 147.86%
ARDX Highest Price Target Wall Street Target
15 USD 220.51%
Price
Max Price Target
Min Price Target
Average Price Target
1616141412121010886644Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Ardelyx, Inc.
image
Sold
0-3 MONTHS
848 K USD 4
3-6 MONTHS
1.13 M USD 6
6-9 MONTHS
1.65 M USD 7
9-12 MONTHS
7.59 M USD 8
Bought
389 K USD 1
0-3 MONTHS
2.99 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. globenewswire.com - 2 weeks ago
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management. globenewswire.com - 3 weeks ago
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was accepted as a poster presentation at the National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 10-13, 2025, in Boston. globenewswire.com - 1 month ago
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy globenewswire.com - 1 month ago
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express + The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, providing investment ideas and sparking discussions on their potential. Edtech company Udemy is seen as on the rise and is a Strong Buy from Weebler Finance. Jumia Technologies shows resilience and growth potential in African e-commerce, despite market skepticism and low stock prices. seekingalpha.com - 2 months ago
Tenapanor Approved in China for Hyperphosphatemia Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval globenewswire.com - 2 months ago
Ardelyx to Participate in Upcoming Investor Conferences WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2025 Global Healthcare Conference Location: Miami, FLPresentation: Tuesday, March 11 at 8:00 a.m. globenewswire.com - 2 months ago
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade) Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments. seekingalpha.com - 2 months ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects. seekingalpha.com - 2 months ago
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript Call End: Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2024 Earnings Conference Call February 20, 2025 8:00 A.M. ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & CEO Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz – Citigroup Dennis Ding – Jefferies Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Julian Harrison – BTIG Ryan Deschner - Raymond James Thomas Yip - H.C. seekingalpha.com - 2 months ago
Ardelyx Tops Estimates as Sales Surge Ardelyx (ARDX -8.10%), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release highlighted considerable progress in the company's commercialization of its two approved drugs, Ibsrela and Xphozah. fool.com - 2 months ago
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
8. Profile Summary

Ardelyx, Inc. ARDX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.12 B
Dividend Yield 0.00%
Description Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Contact 400 Fifth Avenue, Waltham, MA, 02451 https://www.ardelyx.com
IPO Date June 19, 2014
Employees 395
Officers Mr. Michael G. Raab President, Chief Executive Officer & Director Mr. Justin A. Renz CPA, MBA Chief Financial & Operations Officer Mr. Eric Duane Foster Chief Commercial Officer Mr. David P. Rosenbaum Chief Development Officer Mr. Robert C. Blanks Chief Regulatory Affairs & Quality Assurance Officer Mr. Mike Kelliher Executive Vice President of Corporate Development & Strategy Mr. Joseph Reilly Senior Vice President of Finance & Principal Accounting Officer Ms. Elizabeth A. Grammer Esq. Chief Legal & Administrative Officer and Secretary Dr. Laura A. Williams M.D., M.P.H. Chief Medical Officer Ms. Caitlin Lowie Vice President of Corporate Communications & Investor Relations